Bushra Osmani
Endocrinology, Diabetes & Metabolism · Columbia, TNNPI 1760746127
Payments from drug & device makers
Across 145 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$348
- Medtronic$305
- Xeris Pharmaceuticals, Inc.$237
- Abbott$236
- BETA Bionics, Inc.$223
- Dexcom, Inc.$217
- plus $1K from 14 others
What the payments were for
- Food & beverage$2,928100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $348 |
| Medtronic | 13 | $305 |
| Xeris Pharmaceuticals, Inc. | 12 | $237 |
| Abbott | 12 | $236 |
| BETA Bionics, Inc. | 4 | $223 |
| Dexcom, Inc. | 20 | $217 |
| Cequr Corporation | 3 | $210 |
| AstraZeneca | 11 | $190 |
| Bayer | 8 | $181 |
| Lilly USA, LLC | 7 | $142 |
| Insulet Corporation | 7 | $134 |
| Tandem Diabetes Care, Inc. | 5 | $118 |
| Boehringer Ingelheim | 6 | $106 |
| AbbVie | 3 | $75 |
| Sanofi-aventis U.S. LLC | 5 | $70 |
| Ascendis Pharma Endocrinology Inc | 2 | $46 |
| IBSA Pharma Inc. | 1 | $35 |
| Zealand Pharma US, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Sequel Med Tech, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,928 in reported general payments places this provider in the 40th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 365 | $486,279 |
| OzempicSemaglutide | 223 | $243,020 |
| JardianceEmpagliflozin | 197 | $233,330 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 200 | $160,275 |
| FarxigaDapagliflozin Propanediol | 77 | $74,740 |
| Tresiba Flextouch U-200Insulin Degludec | 69 | $70,723 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 42 | $40,613 |
| TrulicityDulaglutide | 34 | $39,664 |
| JanuviaSitagliptin Phosphate | 46 | $31,202 |
| Humalog Kwikpen U-200Insulin Lispro | 14 | $28,755 |
| RybelsusSemaglutide | 34 | $27,656 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $23,766 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $20,282 |
| Humalog Kwikpen U-100Insulin Lispro | 41 | $10,995 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $9,338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $142 | $533,927459 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $348 | $277,533288 claims |
| Boehringer IngelheimJardiance | $106 | $233,330197 claims |
| AstraZenecaFarxiga | $190 | $74,74077 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $70 | $9,33811 claims |
| AbbVieSynthroid | $75 | $2,89337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Columbia
- Stephen SharpNashville$25.9M
- Lisa UsdanMemphis$14.3M
- Kathryn DahirNashville$11M
- David HuffmanChattanooga$2.4M
- Pedro VelasquezMemphis$2.4M
- Craig WierumNashville$1.7M
- Alan CohenMemphis$1.5M
- Terri JerkinsNashville$1.2M
- Pascal DauphinHendersonville$925K
- Aidar GosmanovMemphis$833K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.